AlzforumCRISPR Screen Pulls Down Fresh Targets for C9ORF72 ALSAlzforumProtein products of an expanded repeat sequence in the C9ORF72 gene harm neurons in myriad ways, ultimately leading to amyotrophic lateral sclerosis (ALS) and/or frontotemporal demen… Continue reading
Pain News Network |
FDA Moves Forward on Stem Cells
Pain News Network In a special report published in The New England Journal of Medicine, the FDA makes a clear and positive shift in its stem cell policy – conceding that the old paradigm of drug approval just doesn’t work for stem cells. The report, entitled “Balancing … |
Futurism |
A Stem Cell Patch Could Heal Hearts Damaged By Cardiac Arrest
Futurism But a team of researchers at the University of Cambridge’s Stem Cell Institute in the U.K. is developing an innovative way to repair heart tissue. The team’s solution doesn’t require a donor heart at all — instead, they’ve used stem cells to grow live … |
Madison.com |
Here’s Why CRISPR Therapeutics AG Gained as Much as 14% Today
Madison.com Shares of gene-editing pioneer CRISPR Therapeutics AG (NASDAQ: CRSP) dropped 14% today after the company announced full-year 2017 earnings and provided shareholders with a business update for what to expect in the year ahead. In the fourth quarter of … CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsGlobeNewswire (press release) Should You Consider CRISPR Therapeutics AG (CRSP) Based on Their Fundamentals?US Trade Media UPDATE: CRISPR Therapeutics (CRSP) PT Raised to $59 at Barclays, Street HighStreetInsider.com Zacks all 72 news articles » |
GlobeNewswire (press release) |
Here’s Why CRISPR Therapeutics AG Gained as Much as 14% Today
Motley Fool Shares of gene-editing pioneer CRISPR Therapeutics AG (NASDAQ:CRSP) dropped 14% today after the company announced full-year 2017 earnings and provided shareholders with a business update for what to expect in the year ahead. In the fourth quarter of … CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsGlobeNewswire (press release) CRISPR Therapeutics AG (NASDAQ:CRSP): Financial Strength AnalysisSimply Wall St Should You Consider CRISPR Therapeutics AG (CRSP) Based on Their Fundamentals?US Trade Media Zacks all 73 news articles » |
|
Emerging Advances for Immunotherapy in Urothelial Cancer
OncLive Jonathan Rosenberg, MD: These are very exciting times—in the treatment of advanced bladder cancer and even in non–muscle invasive bladder cancer. We have a whole new therapeutic armamentarium that we’re understanding how to better use in this disease … |